{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=83", "query": { "condition": "Melanoma Neoplasms", "page": 83 }, "page_size": 10 }, "pagination": { "page": 83, "page_size": 10, "total_count": 2209, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=84&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=82&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T19:14:12.635Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04201223", "title": "Family Lifestyles, Actions, and Risk Education Intervention: Version 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma", "Child" ], "interventions": [ { "name": "FLARE Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "8 Years to 110 Years" }, "enrollment_count": 752, "start_date": "2020-04-07", "completion_date": "2025-01-28", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04201223" }, { "nct_id": "NCT00818480", "title": "An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Melanoma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "YM155", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2006-02", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2015-09-04", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 3, "location_summary": "San Antonio, Texas • Salt Lake City, Utah", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00818480" }, { "nct_id": "NCT01266603", "title": "High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "HDIL-2", "type": "DRUG" }, { "name": "recMAGE-A3 + AS15", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2011-02-22", "completion_date": "2018-11-01", "has_results": true, "last_update_posted_date": "2020-02-19", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01266603" }, { "nct_id": "NCT07281924", "title": "Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Liver Metastases" ], "interventions": [ { "name": "Nivolumab and Relatlimab", "type": "DRUG" }, { "name": "Melphalan", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-11", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281924" }, { "nct_id": "NCT05571839", "title": "A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Melanoma", "Non-small Cell Lung Cancer", "Colorectal Neoplasms", "Pancreatic Neoplasms", "Mesothelioma" ], "interventions": [ { "name": "PF-08046049", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-01-03", "completion_date": "2026-06-01", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 27, "location_summary": "Los Angeles, California • Pasadena, California • San Francisco, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05571839" }, { "nct_id": "NCT03739931", "title": "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma", "Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma" ], "interventions": [ { "name": "mRNA-2752", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2018-11-27", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 16, "location_summary": "San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739931" }, { "nct_id": "NCT01416831", "title": "Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Radiation therapy and high-dose IL-2", "type": "OTHER" }, { "name": "High-dose IL-2", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2011-07-01", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01416831" }, { "nct_id": "NCT00863330", "title": "Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "Tumor Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2009-02", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00863330" }, { "nct_id": "NCT03819296", "title": "Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage 0 Cutaneous Melanoma AJCC v8", "Clinical Stage I Cutaneous Melanoma AJCC v8", "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8", "Clinical Stage II Cutaneous Melanoma AJCC v8", "Clinical Stage IIA Cutaneous Melanoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Colitis", "Lung Non-Small Cell Carcinoma", "Malignant Genitourinary System Neoplasm", "Malignant Solid Neoplasm", "Pathologic Stage 0 Cutaneous Melanoma AJCC v8", "Pathologic Stage I Cutaneous Melanoma AJCC v8", "Pathologic Stage IA Cutaneous Melanoma AJCC v8", "Pathologic Stage IB Cutaneous Melanoma AJCC v8", "Pathologic Stage II Cutaneous Melanoma AJCC v8", "Pathologic Stage IIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIC Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Stage 0 Lung Cancer AJCC v8", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "OTHER" }, { "name": "Endoscopic Procedure", "type": "PROCEDURE" }, { "name": "Fecal Microbiota Transplantation", "type": "PROCEDURE" }, { "name": "Infliximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vedolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2021-02-21", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819296" }, { "nct_id": "NCT01586195", "title": "Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 31, "start_date": "2011-10-31", "completion_date": "2015-04-30", "has_results": true, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-11-03T19:14:12.635Z", "location_count": 15, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01586195" } ] }